I am buying, 5% of my portfolio.
My opinion: downturn caused by 6 of 8 humans in clinical trial (bad news), and by a correction of too rapid GILD growth last two months ('normal').
Article says: "It isn't so much that this happened ... The critical key is how does Gilead respond to what just happened."
Top management not amateurs.
"downturn caused by 6 of 8 humans"
read 8 of 8 or actually 10 of 10.
2 probably relased later but GILD did not want to report.
2 unavailable or quit because of side effect or drug did not work at all.
Ask GILD to stop manufacturing data.
This is not a management problem, unless you are talking about gilding the lily. This is a science problem, and if they don't have a remediation plan or worthy ideas on how to defeat the disease, then more price declines are possible. Not trying to trivialize the problem, but sooner or later, the drug has to deliver.